The anti-EGFR antibody cetuximab sensitizes human head and neck squamous cell carcinoma cells to radiation in part through inhibiting radiation-induced upregulation of HIF-1α

Cancer Letters

Volumn 322, Issue 1, 2012, Pages 78-85

  Lu, Haiquan ^a,b   Liang, Ke ^a   Lu, Yang ^a   Fan, Zhen ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Cetuximab; EGFR; HIF 1alpha; Radiation

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; SMALL INTERFERING RNA;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER RADIOTHERAPY; CARCINOMA CELL; CONTROLLED STUDY; DOWN REGULATION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; IONIZING RADIATION; MOLECULAR MECHANICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; RADIOSENSITIZATION; UPREGULATION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; GENES, RAS; HEAD AND NECK NEOPLASMS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, SMALL INTERFERING; UP-REGULATION;

EID: 84862785887     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.02.012     Document Type: Article

References (51)

1. Ang K.K. Multidisciplinary management of locally advanced SCCHN: optimizing treatment outcomes. Oncologist 2008, 13:899-910.
2. Ko C., Citrin D. Radiotherapy for the management of locally advanced squamous cell carcinoma of the head and neck. Oral Dis. 2009, 15:121-132.
3. Ishitoya J., Toriyama M., Oguchi N., Kitamura K., Ohshima M., Asano K., Yamamoto T. Gene amplification and overexpression of EGF receptor in squamous cell carcinomas of the head and neck. Br. J. Cancer 1989, 59:559-562.
4. Grandis J.R., Tweardy D.J. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res. 1993, 53:3579-3584.
5. Milas L., Mason K., Hunter N., Petersen S., Yamakawa M., Ang K., Mendelsohn J., Fan Z. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin. Cancer Res. 2000, 6:701-708.
6. Liang K., Ang K.K., Milas L., Hunter N., Fan Z. The epidermal growth factor receptor mediates radioresistance. Int. J Radiat. Oncol. Biol. Phys. 2003, 57:246-254.
7. Nakata E., Hunter N., Mason K., Fan Z., Ang K.K., Milas L. C225 antiepidermal growth factor receptor antibody enhances the efficacy of docetaxel chemoradiotherapy. Int. J Radiat. Oncol. Biol. Phys. 2004, 59:1163-1173.
8. Bonner J.A., Buchsbaum D.J., Rogers B.E., Grizzle W.E., Trummell H.Q., Curiel D.T., Fiveash J.B., Ove R., Raisch K.P. Adenoviral vector-mediated augmentation of epidermal growth factor receptor (EGFr) enhances the radiosensitization properties of anti-EGFr treatment in prostate cancer cells. Int. J. Radiat. Oncol. Biol. Phys. 2004, 58:950-958.
9. Bonner J.A., Buchsbaum D.J., Russo S.M., Fiveash J.B., Trummell H.Q., Curiel D.T., Raisch K.P. Anti-EGFR-mediated radiosensitization as a result of augmented EGFR expression. Int. J. Radiat. Oncol. Biol. Phys. 2004, 59:2-10.
10. Chung C.H., Zhang Q., Hammond E.M., Trotti A.M., Wang H., Spencer S., Zhang H.Z., Cooper J., Jordan R., Rotman M.H., Ang K.K. Integrating epidermal growth factor receptor assay with clinical parameters improves risk classification for relapse and survival in head-and-neck squamous cell carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 2010.
11. Huang S.M., Bock J.M., Harari P.M. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res. 1999, 59:1935-1940.
12. Bonner J.A., Harari P.M., Giralt J., Azarnia N., Shin D.M., Cohen R.B., Jones C.U., Sur R., Raben D., Jassem J., Ove R., Kies M.S., Baselga J., Youssoufian H., Amellal N., Rowinsky E.K., Ang K.K. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 2006, 354:567-578.
13. Bonner J.A., Harari P.M., Giralt J., Cohen R.B., Jones C.U., Sur R.K., Raben D., Baselga J., Spencer S.A., Zhu J., Youssoufian H., Rowinsky E.K., Ang K.K. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010, 11:21-28.
14. Gray L.H., Conger A.D., Ebert M., Hornsey S., Scott O.C. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br. J. Radiol. 1953, 26:638-648.
15. Thomlinson R.H., Gray L.H. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br. J Cancer 1955, 9:539-549.
16. Roots R., Smith K.C. On the nature of the oxygen effect on x-ray-induced DNA single-strand breaks in mammalian cells. Int. J. Radiat. Biol. Relat Stud. Phys. Chem. Med. 1974, 26:467-480.
17. Quintiliani M. Modification of radiation sensitivity: the oxygen effect. Int. J. Radiat. Oncol. Biol. Phys. 1979, 5:1069-1076.
18. Brizel D.M., Scully S.P., Harrelson J.M., Layfield L.J., Bean J.M., Prosnitz L.R., Dewhirst M.W. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res. 1996, 56:941-943.
19. Brizel D.M., Sibley G.S., Prosnitz L.R., Scher R.L., Dewhirst M.W. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int. J. Radiat. Oncol. Biol. Phys. 1997, 38:285-289.
20. Hockel M., Schlenger K., Aral B., Mitze M., Schaffer U., Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res. 1996, 56:4509-4515.
21. Nordsmark M., Overgaard J. A confirmatory prognostic study on oxygenation status and loco-regional control in advanced head and neck squamous cell carcinoma treated by radiation therapy. Radiother. Oncol. 2000, 57:39-43.
22. Nordsmark M., Alsner J., Keller J., Nielsen O.S., Jensen O.M., Horsman M.R., Overgaard J. Hypoxia in human soft tissue sarcomas: adverse impact on survival and no association with p53 mutations. Br. J. Cancer 2001, 84:1070-1075.
23. Maxwell P.H., Pugh C.W., Ratcliffe P.J. Inducible operation of the erythropoietin 3' enhancer in multiple cell lines: evidence for a widespread oxygen-sensing mechanism. Proc. Natl. Acad. Sci. USA 1993, 90:2423-2427.
24. Firth J.D., Ebert B.L., Pugh C.W., Ratcliffe P.J. Oxygen-regulated control elements in the phosphoglycerate kinase 1 and lactate dehydrogenase A genes: similarities with the erythropoietin 3' enhancer. Proc. Natl. Acad. Sci. USA 1994, 91:6496-6500.
25. Semenza G.L., Roth P.H., Fang H.M., Wang G.L. Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. J. Biol. Chem. 1994, 269:23757-23763.
26. Semenza G.L. Hypoxia, clonal selection, and the role of HIF-1 in tumor progression. Crit Rev. Biochem. Mol. Biol. 2000, 35:71-103.
27. Semenza G.L. Intratumoral hypoxia, radiation resistance, and HIF-1. Cancer Cell 2004, 5:405-406.
28. Aebersold D.M., Burri P., Beer K.T., Laissue J., Djonov V., Greiner R.H., Semenza G.L. Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res. 2001, 61:2911-2916.
29. Liu J., Zhang J., Wang X., Li Y., Chen Y., Li K., Zhang J., Yao L., Guo G. HIF-1 and NDRG2 contribute to hypoxia-induced radioresistance of cervical cancer HeLa cells. Exp. Cell Res. 2010, 316:1985-1993.
30. Unruh A., Ressel A., Mohamed H.G., Johnson R.S., Nadrowitz R., Richter E., Katschinski D.M., Wenger R.H. The hypoxia-inducible factor-1 alpha is a negative factor for tumor therapy. Oncogene 2003, 22:3213-3220.
31. Moeller B.J., Cao Y., Li C.Y., Dewhirst M.W. Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell 2004, 5:429-441.
32. Harada H., Kizaka-Kondoh S., Li G., Itasaka S., Shibuya K., Inoue M., Hiraoka M. Significance of HIF-1-active cells in angiogenesis and radioresistance. Oncogene 2007, 26:7508-7516.
33. Schwartz D.L., Powis G., Thitai-Kumar A., He Y., Bankson J., Williams R., Lemos R., Oh J., Volgin A., Soghomonyan S., Nishii R., Alauddin M., Mukhopadhay U., Peng Z., Bornmann W., Gelovani J. The selective hypoxia inducible factor-1 inhibitor PX-478 provides in vivo radiosensitization through tumor stromal effects. Mol. Cancer Ther. 2009, 8:947-958.
34. Moon S.Y., Chang H.W., Roh J.L., Kim G.C., Choi S.H., Lee S.W., Cho K.J., Nam S.Y., Kim S.Y. Using YC-1 to overcome the radioresistance of hypoxic cancer cells. Oral Oncol. 2009, 45:915-919.
35. Kim J.W., Kim H.P., Im S.A., Kang S., Hur H.S., Yoon Y.K., Oh D.Y., Kim J.H., Lee D.S., Kim T.Y., Bang Y.J. The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines. Cancer Lett. 2008, 272:296-306.
36. Kim W.Y., Oh S.H., Woo J.K., Hong W.K., Lee H.Y. Targeting heat shock protein 90 overrides the resistance of lung cancer cells by blocking radiation-induced stabilization of hypoxia-inducible factor-1alpha. Cancer Res. 2009, 69:1624-1632.
37. Singh-Gupta V., Zhang H., Banerjee S., Kong D., Raffoul J.J., Sarkar F.H., Hillman G.G. Radiation-induced HIF-1alpha cell survival pathway is inhibited by soy isoflavones in prostate cancer cells. Int. J. Cancer 2009, 124:1675-1684.
38. Li F., Sonveaux P., Rabbani Z.N., Liu S., Yan B., Huang Q., Vujaskovic Z., Dewhirst M.W., Li C.Y. Regulation of HIF-1alpha stability through S-nitrosylation. Mol. Cell 2007, 26:63-74.
39. An W.G., Kanekal M., Simon M.C., Maltepe E., Blagosklonny M.V., Neckers L.M. Stabilization of wild-type p53 by hypoxia-inducible factor 1alpha. Nature 1998, 392:405-408.
40. Carmeliet P., Dor Y., Herbert J.M., Fukumura D., Brusselmans K., Dewerchin M., Neeman M., Bono F., Abramovitch R., Maxwell P., Koch C.J., Ratcliffe P., Moons L., Jain R.K., Collen D., Keshert E., Keshet E. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 1998, 394:485-490.
41. Moeller B.J., Dreher M.R., Rabbani Z.N., Schroeder T., Cao Y., Li C.Y., Dewhirst M.W. Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity. Cancer Cell 2005, 8:99-110.
42. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 2003, 3:721-732.
43. Harris A.L. Hypoxia-a key regulatory factor in tumour growth. Nat. Rev. Cancer 2002, 2:38-47.
44. Li X., Lu Y., Liang K., Pan T., Mendelsohn J., Fan Z. Requirement of hypoxia-inducible factor-1alpha down-regulation in mediating the antitumor activity of the anti-epidermal growth factor receptor monoclonal antibody cetuximab. Mol. Cancer Ther. 2008, 7:1207-1217.
45. Luwor R.B., Lu Y., Li X., Mendelsohn J., Fan Z. The antiepidermal growth factor receptor monoclonal antibody cetuximab/C225 reduces hypoxia-inducible factor-1 alpha, leading to transcriptional inhibition of vascular endothelial growth factor expression. Oncogene 2005, 24:4433-4441.
46. Lu Y., Liang K., Li X., Fan Z. Responses of cancer cells with wild-type or tyrosine kinase domain-mutated epidermal growth factor receptor (EGFR) to EGFR-targeted therapy are linked to downregulation of hypoxia-inducible factor-1alpha. Mol. Cancer 2007, 6:63.
47. Lu Y., Li X., Lu H., Fan Z. 1, 9-Pyrazoloanthrones downregulate HIF-1alpha and sensitize cancer cells to cetuximab-mediated anti-EGFR therapy. PLoS One 2010, 5:e15823.
48. Luwor R.B., Lu Y., Li X., Liang K., Fan Z. Constitutively active Harvey Ras confers resistance to epidermal growth factor receptor-targeted therapy with cetuximab and gefitinib. Cancer Lett. 2011, 306:85-91.
49. Wheeler D.L., Huang S., Kruser T.J., Nechrebecki M.M., Armstrong E.A., Benavente S., Gondi V., Hsu K.T., Harari P.M. Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene 2008, 27:3944-3956.
50. Harari P.M., Wheeler D.L., Grandis J.R. Molecular target approaches in head and neck cancer: epidermal growth factor receptor and beyond. Semin. Radiat. Oncol. 2009, 19:63-68.
51. Chen L.F., Cohen E.E., Grandis J.R. New strategies in head and neck cancer: understanding resistance to epidermal growth factor receptor inhibitors. Clin. Cancer Res. 2010, 16:2489-2495.